SyntheticMR today announced that its new product package SyMRI MSK has received CE-mark, meaning that it can now be marketed and sold in Europe. In our view, the European clearance for SyMRI MSK marks an important step as it significantly expands the addressable market for SyMRI. We expect SyMRI MSK to also be regulatory cleared and launched in the US market during H2 2021.

Länk till analysen